Related Experiment Video
Updated: May 2, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
[Heparin for treatment of sepsis: a systemic review]
Zhiyong Liu1, Hong Zhu, Xiaochun Ma
1Department of Critical Care Medicine, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, China. Corresponding author: Ma Xiaochun,
Insights
Heparin treatment significantly reduces 28-day mortality in sepsis patients. This study indicates heparin is safe and effective for sepsis, improving outcomes and reducing intensive care unit stays.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Hematology
Context:
- Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
- Current sepsis management focuses on early antibiotics, fluid resuscitation, and organ support.
- The role of anticoagulation in sepsis remains a subject of investigation.
Purpose:
- To systematically review the efficacy and safety of heparin in the treatment of sepsis.
- To evaluate heparin's impact on mortality, coagulation parameters, organ dysfunction, and length of stay in sepsis patients.
Summary:
- A meta-analysis of 17 randomized controlled trials (RCTs) involving 1,167 participants was conducted.
- Heparin significantly decreased 28-day mortality (OR=0.59) and corrected sepsis-induced platelet reduction (MD=13.94).
- Heparin also lowered Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, reduced multiple organ dysfunction syndrome (MODS) incidence (OR=0.32), and shortened intensive care unit (ICU) stay.
Impact:
- Heparin demonstrates potential as an adjunctive therapy for sepsis, improving survival and organ function.
- The findings suggest heparin is safe, with no significant increase in bleeding incidence.
- Further large-scale, well-designed RCTs are warranted to confirm these benefits and establish optimal protocols.
Objective:
To systemically review the efficacy and safety of heparin for treatment of sepsis.
Methods:
Database search of IM/MEDLINE, Cochrane Library, SCIE, CBM, CNKI, VIP Data, WanFang Data (from January 2000 to June 2012) was conducted. The quality of included randomized controlled trials (RCTs) about heparin for treatment of sepsis was assessed, and relevant data were extracted according to the inclusion and exclusion criteria. Then meta analysis was performed using RevMan 5.1.
Results:
17 trials with 1 167 participants were included. The results of meta-analysis showed: compared with the control group, heparin significantly decreased 28-day mortality in patients with sepsis [odds ratio (OR)=0.59, 95% confidence interval (95%CI) 0.45-0.77, P=0.0001]; heparin did not deteriorate coagulation disorders, but corrected sepsis-induced platelet (PLT) count reduction [mean difference (MD)=13.94, 95%CI 10.15 to 17.72, P<0.000 01], while it had no significant effect on the activated partial thromboplastin time (APTT) and prothrombin time (PT, APTT: MD=-3.18, 95%CI -6.88 to 0.53, P=0.09; PT: MD=-0.68, 95%CI -1.48 to 0.12, P=0.09). There was no significant difference between the two groups in the incidence of bleeding either. Acute physiology and chronic health evaluation II (APACHEII) score of heparin group was significantly lower than that of the control group (MD=-2.58, 95%CI -3.29 to -1.87, P<0.000 01), and the incidence of multiple organ dysfunction syndrome (MODS) was significantly lower than that of the control group (OR=0.32, 95%CI 0.17 to 0.61, P=0.000 6). In addition, heparin could shorten intensive care unit (ICU) stay (MD=-4.43, 95%CI -6.79 to -2.07, P=0.000 2), whereas it showed no significant effect on the total length of hospital stay.
Conclusions:
Heparin can ameliorate sepsis, and has high degree of safety and lower hospital expense. Due to limitation of the quality of included studies, larger sample and well-designed RCTs are needed to further support this conclusion.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Acute Inflammation II: Local and Systemic Effects
Pulmonary Embolism III: Nursing Management

